Burbank Jeffrey H 4

4 · NxStage Medical, Inc. · Filed Feb 25, 2019

Form 4

Period: 2019-02-21

DirectorPresident & CEO

Transactions

Disposition to Issuer
Stock Option (Right to Buy)
2019-02-21−205,058→ 0 total
Exercise: $16.66From: 2015-04-03Exp: 2025-03-02→ Common Stock (205,058 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-02-21−268,159→ 0 total
Exercise: $15.58From: 2016-04-09Exp: 2026-03-08→ Common Stock (268,159 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-02-21−149,567→ 0 total
Exercise: $27.89From: 2017-04-09Exp: 2027-03-08→ Common Stock (149,567 underlying)
Disposition to Issuer
Restricted Stock Unit
2019-02-21−34,928→ 0 total
Exercise: $0.00From: 2018-03-09Exp: 2020-03-09→ Common Stock (34,928 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-02-21−189,456→ 0 total
Exercise: $11.03From: 2013-04-04Exp: 2023-03-03→ Common Stock (189,456 underlying)
Disposition to Issuer
Common Stock
2019-02-21$30.00/sh−781,646$23,449,380→ 0 total
Disposition to Issuer
Stock Option (Right to Buy)
2019-02-21−39,062→ 0 total
Exercise: $18.48From: 2012-04-09Exp: 2019-03-08→ Common Stock (39,062 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-02-21−175,256→ 0 total
Exercise: $14.66From: 2014-04-10Exp: 2024-03-09→ Common Stock (175,256 underlying)

Footnotes (3)

[F1]Disposed of under Merger Agreement with Fresenius Medical Care Holdings, Inc. in which all outstanding shares of Issuer's Common Stock were converted into the right to receive $30 per share in cash.
[F2]This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price.
[F3]These performance shares were canceled in the Merger in exchange for an amount in cash equal to the product of the total number of performance shares multiplied by the Merger Consideration of $30 per share.

Documents

1 file